| Avante At Orlando Inc | |
| 2000 North Semoran Boulevard, Orlando, Florida 32807 | |
| (407) 671-5400 | |
| Name | Avante At Orlando Inc |
|---|---|
| Location | 2000 North Semoran Boulevard, Orlando, Florida |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 118 |
| Occupancy Rate | 85.08% |
| Medicare ID (CCN) | 106027 |
| Legal Business Name | Avante At Orlando, Inc. |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1750445912 |
| Organization Name | AVANTE AT ORLANDO, INC. |
| Address | 2000 N Semoran Blvd, Orlando, FL 32807 |
| Phone Number | 407-671-5400 |
News Archive
Neogenix Oncology, Inc. has announced that the company's novel antibody NEO-101, which targets pancreatic and colorectal cancer cells, has been selected as one of Windhover's 2011 Top 10 Projects to Watch.
For the first time, UCLA researchers have recreated the ability of mammalian cells to self-organize, forming evenly spaced patterns in a test tube. Published in the June 22, 2004 issue of the Proceedings of the National Academy of Sciences, the findings may help improve methods for regenerating tissue, controlling birth defects and developing new treatments for specific diseases.
XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced the initiation of a Phase 2 clinical trial of XOMA 052, its antibody to interleukin-1 beta (IL-1 beta), in Type 1 diabetes patients. Funding for the trial is being provided by the Juvenile Diabetes Research Foundation International, the largest patient advocacy organization of Type 1 diabetes research worldwide.
MannKind Corporation announced that it was informed today by the Food and Drug Administration that the FDA will not be able to complete the review of MannKind's new drug application (NDA) for its ultra rapid-acting insulin therapy by the action date of January 16, 2010.
That snake heading towards you may be further away than it appears. Fear can skew our perception of approaching objects, causing us to underestimate the distance of a threatening one, finds a study published in Current Biology.
› Verified 5 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Neogenix Oncology, Inc. has announced that the company's novel antibody NEO-101, which targets pancreatic and colorectal cancer cells, has been selected as one of Windhover's 2011 Top 10 Projects to Watch.
For the first time, UCLA researchers have recreated the ability of mammalian cells to self-organize, forming evenly spaced patterns in a test tube. Published in the June 22, 2004 issue of the Proceedings of the National Academy of Sciences, the findings may help improve methods for regenerating tissue, controlling birth defects and developing new treatments for specific diseases.
XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced the initiation of a Phase 2 clinical trial of XOMA 052, its antibody to interleukin-1 beta (IL-1 beta), in Type 1 diabetes patients. Funding for the trial is being provided by the Juvenile Diabetes Research Foundation International, the largest patient advocacy organization of Type 1 diabetes research worldwide.
MannKind Corporation announced that it was informed today by the Food and Drug Administration that the FDA will not be able to complete the review of MannKind's new drug application (NDA) for its ultra rapid-acting insulin therapy by the action date of January 16, 2010.
That snake heading towards you may be further away than it appears. Fear can skew our perception of approaching objects, causing us to underestimate the distance of a threatening one, finds a study published in Current Biology.
› Verified 5 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 11.7 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 11.23 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 55.75 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 1.02 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 0 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 1.93 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 4.18 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 95.82 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 14.84 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 80.72 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 2.9 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 16.84 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 24.77 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 10.59 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 97.37 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 81.35 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 80 | 82.93 |
News Archive
Neogenix Oncology, Inc. has announced that the company's novel antibody NEO-101, which targets pancreatic and colorectal cancer cells, has been selected as one of Windhover's 2011 Top 10 Projects to Watch.
For the first time, UCLA researchers have recreated the ability of mammalian cells to self-organize, forming evenly spaced patterns in a test tube. Published in the June 22, 2004 issue of the Proceedings of the National Academy of Sciences, the findings may help improve methods for regenerating tissue, controlling birth defects and developing new treatments for specific diseases.
XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced the initiation of a Phase 2 clinical trial of XOMA 052, its antibody to interleukin-1 beta (IL-1 beta), in Type 1 diabetes patients. Funding for the trial is being provided by the Juvenile Diabetes Research Foundation International, the largest patient advocacy organization of Type 1 diabetes research worldwide.
MannKind Corporation announced that it was informed today by the Food and Drug Administration that the FDA will not be able to complete the review of MannKind's new drug application (NDA) for its ultra rapid-acting insulin therapy by the action date of January 16, 2010.
That snake heading towards you may be further away than it appears. Fear can skew our perception of approaching objects, causing us to underestimate the distance of a threatening one, finds a study published in Current Biology.
› Verified 5 days ago
Courtyards Of Orlando Care Center Location: 1900 Mercy Drive, Orlando, Florida 32808 Phone: (407) 299-5404 | |
Parks Healthcare And Rehabilitation Center Location: 9311 S Orange Blossom Trl, Orlando, Florida 32837 Phone: (407) 858-0455 | |
Rosewood Health And Rehabilitation Center Location: 3920 Rosewood Way, Orlando, Florida 32808 Phone: (407) 298-9335 | |
Terra Vista Rehab And Health Center Location: 1730 Lucerne Terrace, Orlando, Florida 32806 Phone: (407) 423-1612 | |
Rio Pinar Health Care Location: 7950 Lake Underhill Road, Orlando, Florida 32822 Phone: (407) 658-2046 | |
Palm Garden Of Orlando Location: 654 N Econlockhatchee Trail, Orlando, Florida 32825 Phone: (407) 273-6158 |